Skip to main content
. 2021 May 5;13(5):661. doi: 10.3390/pharmaceutics13050661
Aldox aldoxorubicin
ADC
ANOVA
antibody-drug conjugate
analysis of variance
CDX cell-derived xenograft
Dau daunorubicin
Dox doxorubicin
EphA2 erythropoietin-producing hepatocellular receptor A2
GnRH gonadotropin-releasing hormone
K1 keratin 1
LC/MS liquid chromatography-mass spectrometry
LRP1 LDL receptor-related protein 1
NOD-SCID nonobese diabetic—severe combined immunodeficiency
PARP poly-ADP ribose-polymerase
pCR pathological complete response
PDC peptide-drug conjugate or peptide-doxorubicin conjugate
RP-HPLC reversed-phase high performance liquid chromatography
TNBC triple-negative breast cancer
Trop-2 trophoblast cell-surface antigen 2